Ultragenyx Pharmaceutical (RARE) PT Lowered to $46.00

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its target price decreased by investment analysts at Citigroup from $49.00 to $46.00 in a research note issued to investors on Monday. The brokerage presently has a “sell” rating on the biopharmaceutical company’s stock. Citigroup’s price objective suggests a potential downside of 6.94% from the stock’s current price.

A number of other equities research analysts also recently commented on RARE. Raymond James set a $70.00 target price on Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a research report on Friday, October 26th. Piper Jaffray Companies decreased their target price on Ultragenyx Pharmaceutical to $70.00 and set an “overweight” rating on the stock in a research report on Friday, October 26th. JPMorgan Chase & Co. set a $68.00 target price on Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a research report on Saturday. ValuEngine downgraded Ultragenyx Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Friday, October 12th. Finally, BidaskClub downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Friday, October 19th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and fifteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $77.00.

NASDAQ RARE opened at $49.43 on Monday. The stock has a market capitalization of $2.44 billion, a PE ratio of -6.59 and a beta of 1.95. Ultragenyx Pharmaceutical has a twelve month low of $41.67 and a twelve month high of $90.98.



Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.06) EPS for the quarter, topping analysts’ consensus estimates of ($2.08) by $1.02. The company had revenue of $12.79 million for the quarter, compared to the consensus estimate of $5.63 million. Ultragenyx Pharmaceutical had a negative return on equity of 44.09% and a negative net margin of 703.27%. During the same period in the previous year, the business earned ($1.72) earnings per share. On average, research analysts forecast that Ultragenyx Pharmaceutical will post -4.38 EPS for the current year.

In other Ultragenyx Pharmaceutical news, Director William Aliski sold 3,750 shares of the company’s stock in a transaction that occurred on Wednesday, August 8th. The stock was sold at an average price of $76.66, for a total transaction of $287,475.00. Following the sale, the director now directly owns 72,610 shares in the company, valued at $5,566,282.60. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Shalini Sharp sold 6,700 shares of the company’s stock in a transaction that occurred on Tuesday, September 25th. The shares were sold at an average price of $90.07, for a total value of $603,469.00. Following the sale, the chief financial officer now owns 56,828 shares in the company, valued at $5,118,497.96. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 35,000 shares of company stock worth $2,700,774. Company insiders own 8.40% of the company’s stock.

Hedge funds have recently modified their holdings of the business. Advisors Asset Management Inc. purchased a new stake in Ultragenyx Pharmaceutical during the second quarter valued at approximately $181,000. JBF Capital Inc. purchased a new stake in Ultragenyx Pharmaceutical during the second quarter valued at approximately $384,000. Strs Ohio raised its position in Ultragenyx Pharmaceutical by 358.3% during the second quarter. Strs Ohio now owns 5,500 shares of the biopharmaceutical company’s stock valued at $422,000 after purchasing an additional 4,300 shares during the period. Pier 88 Investment Partners LLC purchased a new stake in Ultragenyx Pharmaceutical during the second quarter valued at approximately $446,000. Finally, Xact Kapitalforvaltning AB raised its position in Ultragenyx Pharmaceutical by 49.7% during the first quarter. Xact Kapitalforvaltning AB now owns 6,623 shares of the biopharmaceutical company’s stock valued at $338,000 after purchasing an additional 2,200 shares during the period. Institutional investors and hedge funds own 96.12% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Read More: Technical Analysis of Stocks and What It Means

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply